Compare ADMA Biologics Inc (ADMA) vs Amer Sports Inc (AS) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Amer Sports (AS) trades at $34.84, down 0.6% on the day, with a neutral technical outlook. The company reported strong Q1 2026 results, beating EPS estimates with $0.38 versus $0.31 expected, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion. Analyst sentiment is overwhelmingly positive, with 12 of 14 analysts rating it a Buy and a consensus price target of $56.00, implying significant upside. Operating cash flow remains robust at $729.80 million for 2025.

The outlook is favorable given consistent earnings beats and raised guidance, but risks include high valuation multiples (P/E of 43.54) and dependence on the Arc'teryx brand's sustained momentum. The stock presents a growth opportunity if execution continues, though premium valuation requires careful monitoring of margin trends and competitive pressures.